Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Multi-location FQHC Uses Updox Telehealth to Sustain Care During COVID and Expand Services Post-Pandemic


News Image

“Through our partnership with Rocking Horse and other community health organizations across the nation, we’re proud to offer a secure, trusted platform that allows quality care to get to those patients in most need, no matter where they are, and evolves with the organization as their needs change.”

Rocking Horse Community Health Center, a Federally Qualified Health Center (FQHC) operating in four Ohio locations, is using telehealth solutions from Updox, the only place to manage healthcare communications across both in-person and virtual care, to supplement community health services and serve their 14,000 patients.

Rocking Horse includes 48 providers and 200 staff members who manage more than 70,000 patient visits a year at four community locations. Care services include basic medical, behavioral health, dental, chiropractics, prenatal, substance abuse counseling and material needs assistance.

The centers were initially evaluating Updox for electronic fax and document management when COVID-19 entered Ohio in March. Over the course of 48 hours, the center went from an initial demo of Updox Video Chat to seeing their first patient via telehealth. More than 90 patients were seen during the first week of the pandemic, allowing care to continue in a safe, secure manner. The centers are now implementing Updox Electronic fax as well.

“Updox’s support in getting us up and running with telehealth solutions made a tremendous impact on our ability to deliver essential care. We reached out on a Tuesday and were seeing patients via telehealth by Thursday,” says Kent Youngman, CEO, Rocking Horse Community Center. “Telehealth not only allowed us to maintain our patient volume, it ensured that community members in need, who relied on our services, were still able to receive them.”

“Through our partnership with Rocking Horse and other community health organizations across the nation, we’re proud to offer a secure, trusted platform that allows quality care to get to those patients in most need, no matter where they are, and evolves with the organization as their needs change,” says Michael Morgan, CEO, Updox. “Virtual care bridges a gap that exists in healthcare and provides options for patients to access care no matter their location or situation. Patients appreciate the convenience telehealth offers and it allows healthcare to expand services outside of physical location.”

“We will definitely continue offering telehealth post-COVID. More than 30 percent of our patients indicate a preference for using that to continue their care,” says Stacy Lee, director of Operations, Rocking Horse. “Prior to the pandemic, we were working on a transportation program to get people to the office for care. We’ll be able to use telehealth for that and that allows us to reach patients we may not have been able to see otherwise.”

About Rocking Horse Community Health Center

As a Federally Qualified Health Center and a certified Primary Care Medical Home, Rocking Horse Community Health Center provides quality family and pediatric healthcare, behavioral health and counseling, psychiatry, women’s healthcare including obstetrics and gynecology, chiropractic services and comprehensive dental care. In addition to clinical care, the Center also provides case management services, financial advocates and material assistance programs to connect patients to the resources they need. Community Outreach programming helps with school supplies, holiday presents and warm clothing for families in need. Rocking Horse Community Health Center creates a caring environment where quality services empower adults and children to improve their physical and emotional health. Learn more at http://www.rockinghorsecenter.org.

About Updox

The only place to manage healthcare communications across both in-person and virtual care, Updox offers one consolidated inbox for healthcare providers to manage the entire patient journey and office productivity. Through an all-in-one platform, Updox provides a broad set of capabilities for virtual health, patient engagement, and paperless office efficiency that work together to reduce costs and drive revenue. Updox is integrated with more than 100 electronic health records (EHR) and pharmacy management systems and serves more than 560,000 users and 210 million patients. Updox customers also benefit from an engaged user community for benchmarking, idea exchange and networking. Learn how we simplify the business of healthcare. Visit http://www.updox.com or follow the company on Twitter, LinkedIn and Facebook.

Share article on social media or email:



Jardiance® associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark


We look forward to applying these insights to continue ensuring access to products that provide both clinical and cost savings benefits for our members-Kayse Reitmeyer, Manager of Pharmacy Contracting, Highmark

Highmark and Boehringer Ingelheim announced positive results from their outcomes-based agreement, which showed that adults with type 2 diabetes and known cardiovascular disease who took Jardiance® (empagliflozin) had a lower annual total cost of care compared with those prescribed other branded or generic anti-hyperglycemic medications. Jardiance is an oral prescription medicine indicated along with diet and exercise to lower blood sugar in adults with type 2 diabetes and to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease. Jardiance is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine). Please see Important Safety Information below. Jardiance is a product in the Boehringer Ingelheim and Eli Lilly and Company alliance portfolio.

The innovative outcomes-based agreement, launched in 2018, was designed to evaluate the total cost of care for in-scope patients over a one-year period, using actuarial analytical methods. In the retrospective analysis of pharmacy and medical claims for adults with type 2 diabetes and known cardiovascular disease, the patients on Jardiance demonstrated a reduction in medical costs of over 30%. Factoring in both medical and pharmacy costs, the overall total cost of care reduction was more than 20% for patients on Jardiance.

“The results of our outcomes-based agreement with Highmark demonstrated that Jardiance can help reduce the economic burden of type 2 diabetes and cardiovascular disease, underscoring its value to the healthcare system,” said Christine Marsh, senior vice president, Market Access, Boehringer Ingelheim Pharmaceuticals, Inc. “We are proud of our unique partnership with Highmark and our efforts show how pharmaceutical companies and payors can work together to ensure people living with these chronic, debilitating conditions get the best, guideline-directed care while lowering total medical costs.”

“Highmark is committed to developing solutions that provide access to treatments that improve outcomes and reduce the total cost of care for chronic conditions like diabetes and heart disease, which have a huge impact on our members and on our healthcare system,” said Kayse Reitmeyer, Manager of Pharmacy Contracting, Highmark. “The reduction in medical costs seen in this analysis may stem from fewer medical and hospital interventions related to diabetes and heart disease for Highmark members in the Jardiance group. We are pleased with the results of our outcomes-based agreement with Boehringer Ingelheim, and we look forward to applying these insights to continue ensuring access to products that provide both clinical and cost savings benefits for our members.”

Over 34 million Americans are living with diabetes, with type 2 diabetes accounting for 90 to 95% of all cases. Type 2 diabetes is associated with an increased risk of cardiovascular disease and its complications. Type 2 diabetes and its complications impose a huge burden on the healthcare system. Annual medical expenses for people with diagnosed diabetes in 2017 was $237 billion representing a 26% increase over a five-year period, and costs for cardiovascular disease are projected to rise to more than $1 trillion by 2035.

About Type 2 Diabetes and Cardiovascular Disease

Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin. More than 463 million people worldwide have diabetes, of which 232 million are estimated to be undiagnosed. By 2045, the number of people with diabetes is expected to rise to 700 million people worldwide. Type 2 diabetes is the most common form of diabetes.

Due to the complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, cardiovascular disease is a major complication and the leading cause of death associated with diabetes. One in two people with type 2 diabetes worldwide die from a cardiovascular event.

What is JARDIANCE? (http://www.jardiance.com)

JARDIANCE is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

JARDIANCE is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

IMPORTANT SAFETY INFORMATION

Do not take JARDIANCE if you are allergic to empagliflozin or any of the ingredients in JARDIANCE.

Do not take JARDIANCE if you have severe kidney problems or are on dialysis.

JARDIANCE can cause serious side effects, including:


  •     Dehydration. JARDIANCE can cause some people to have dehydration (the loss of body water and salt). Dehydration may cause you to feel dizzy, faint, light-headed, or weak, especially when you stand up.

You may be at a higher risk of dehydration if you:

  •     have low blood pressure
  •     take medicines to lower your blood pressure, including water pills (diuretics)
  •     are on a low salt diet
  •     have kidney problems
  •     are 65 years of age or older.
  •     Vaginal yeast infection. Women who take JARDIANCE may get vaginal yeast infections. Talk to your doctor if you experience vaginal odor, white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese), and/or vaginal itching.
  •     Yeast infection of the penis. Men who take JARDIANCE may get a yeast infection of the skin around the penis, especially uncircumcised males and those with chronic infections. Talk to your doctor if you experience redness, itching or swelling of the penis, rash of the penis, foul smelling discharge from the penis, and/or pain in the skin around penis.
  •     Ketoacidosis (increased ketones in your blood or urine). Ketoacidosis is a serious condition and may need to be treated in the hospital. Ketoacidosis may lead to death. Ketoacidosis occurs in people with type 1 diabetes and can also occur in people with type 2 diabetes taking JARDIANCE, even if blood sugar is less than 250 mg/dL. Ketoacidosis has also happened in people with diabetes who were sick or who had surgery during treatment with JARDIANCE. Stop taking JARDIANCE and call your doctor right away if you get any of the following symptoms, and if possible, check for ketones in your urine:
  •     nausea        
  •     vomiting
  •     stomach-area (abdominal) pain
  •     tiredness
  •     trouble breathing
  •     Kidney problems. Sudden kidney injury has happened in people taking JARDIANCE. Talk to your doctor right away if you reduce the amount you eat or drink, or if you lose liquids; for example, from vomiting, diarrhea, or being in the sun too long.
  •     Serious urinary tract infections. Serious urinary tract infections can occur in people taking JARDIANCE and may lead to hospitalization. Tell your doctor if you have symptoms of a urinary tract infection, such as a burning feeling when passing urine, a need to urinate often or right away, pain in the lower part of your stomach or pelvis, or blood in the urine. Sometimes people also may have a fever, back pain, nausea or vomiting.
  •     Low blood sugar (hypoglycemia): If you take JARDIANCE with another medicine that can cause low blood sugar, such as sulfonylurea or insulin, your risk of low blood sugar is higher. The dose of your sulfonylurea or insulin may need to be lowered. Symptoms of low blood sugar may include:

o    headache

o    drowsiness

o    weakness

o    dizziness

o    confusion

o    irritability

o    hunger

o    fast heartbeat

o    sweating

o    shaking or feeling jittery

  •     Necrotizing fasciitis. A rare but serious bacterial infection that causes damage to the tissue under the skin in the area between and around your anus and genitals (perineum). This bacterial infection has happened in women and men who take JARDIANCE, and may lead to hospitalization, multiple surgeries, and death. Seek medical attention immediately if you have fever or are feeling very weak, tired or uncomfortable (malaise), and you develop any of the following symptoms in the area between and around your anus and genitals: pain or tenderness, swelling, and redness of skin (erythema).

  •     Allergic (hypersensitivity) reactions. Symptoms of serious allergic reactions to JARDIANCE may include:
  •     swelling of your face, lips, throat and other areas of your skin
  •     difficulty with swallowing or breathing
  •     raised, red areas on your skin (hives)


If you have any of these symptoms, stop taking JARDIANCE and contact your doctor or go to the nearest emergency room right away.

  •     Increased fats in your blood (cholesterol).

The most common side effects of JARDIANCE include urinary tract infections and yeast infections in females.

These are not all the possible side effects of JARDIANCE. For more information, ask your doctor or pharmacist.

Before taking JARDIANCE, tell your doctor if you:

  •     have kidney problems. Your doctor may do blood tests to check your kidneys before and during your treatment with JARDIANCE
  •     have liver problems
  •     have a history of urinary tract infections or problems with urination
  •     are going to have surgery. Your doctor may stop your JARDIANCE before you have surgery. Talk to your doctor if you are having surgery about when to stop taking JARDIANCE and when to start it again
  •     are eating less or there is a change in your diet
  •     have or have had problems with your pancreas, including pancreatitis or surgery on your pancreas
  •     drink alcohol very often, or drink a lot of alcohol in the short term (“binge” drinking)
  •     have any other medical conditions
  •     are pregnant or plan to become pregnant. JARDIANCE may harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with JARDIANCE
  •     are breastfeeding or are planning to breastfeed. JARDIANCE may pass into your breast milk and may harm your baby. Do not breastfeed while taking JARDIANCE

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take water pills (diuretics) or medicines that can lower your blood sugar, such as insulin.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see Prescribing Information and Medication Guide.

CL-JAR-100057 01.27.2020

About Highmark Inc.

One of America’s leading health insurance organizations and an independent licensee of the Blue Cross Blue Shield Association, Highmark Inc. (the Health Plan) and its affiliated health plans (collectively, the Health Plans) work passionately to deliver high-quality, accessible, understandable, and affordable experiences, outcomes, and solutions to customers. As the fourth-largest overall Blue Cross Blue Shield-affiliated organization, Highmark Inc. and its Blue-branded affiliates proudly cover the insurance needs of more than 5.6 million members in Pennsylvania, Delaware, and West Virginia. Its diversified businesses serve group customer and individual needs across the United States through dental insurance and other related businesses. For more information, visit http://www.highmark.com.

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of around $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and is part of the Boehringer Ingelheim group of companies. In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.

Boehringer Ingelheim is committed to improving lives and strengthening our communities. Please visit http://www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives.

For more information, please visit http://www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.

###

Jardiance® is a registered trademark of Boehringer Ingelheim.

MPR-US-101440

CONTACT:

Leilyn Perri

Highmark Health    

717-215-7835

Leilyn.perri@highmarkhealth.org

CONTACT:

Sheryl van der Hilst

Senior Associate Director, Public Relations

Boehringer Ingelheim Pharmaceuticals, Inc.

914-772-7973

sheryl.van_der_hilst@boehringer-ingelheim.com

Torchlight Adds Senior Director of Sales and Business Development and Director of Engineering to Leadership Team


Ann Gargis

“We are extremely pleased to announce that Ann Gargis and Paul Harsha have joined Torchlight,” said Adam Goldberg, M.Ed., Torchlight’s CEO.

Torchlight, a leading provider of employee-caregiver support solutions, announced today that Ann Gargis and Paul Harsha have joined the executive leadership team of the company. Gargis, as Senior Director of Sales and Business Development, is responsible for Torchlight’s sales strategy, market development, and product distribution of the company’s premier caregiver support solutions. Harsha, as Director of Engineering, is leading the Engineering team in support of the company’s accelerated product development initiatives. Both Gargis and Harsha report directly to Adam Goldberg, M.Ed., Torchlight’s CEO.

“We are extremely pleased to announce that Ann Gargis and Paul Harsha have joined Torchlight,” said Goldberg. “Ann’s experience as a caregiver herself, with a proven track record of facilitating successful health and wellbeing outcomes in partnership with employers, health plans, and leading brokers and consultants, makes her the ideal sales leader for Torchlight.”

Before joining Torchlight, Gargis spent the last four years at Mercer, a global HR consulting firm, where she led her team in new client sales. Before Mercer, she was Director of Employer Sales at Benefitfocus and also spent seven years as Corporate Sales Manager for national accounts at ADP. Within the industry, Gargis is also a sponsor of a Women’s Executive Network in Pittsburgh, member of the Executive Women’s Council, Allegheny Conference and a supporter of 412 Food Rescue and the Highmark Caring Place.

“I am thrilled to join the Torchlight team and look forward to bringing Torchlight’s caregiver support solutions to an expanding list of organizations that believe, as we do, that caring is everyone’s business and caring is good business,” said Gargis. “I am also excited to serve as a strong voice for prospects, customers, and partners on the Torchlight leadership team during such a critical time.”

“We are equally fortunate to have Paul join us. Paul’s 25 year career working with startups and technology companies in building quick-moving, productive, customer-focused teams and leading them in taking technology to the next level will be invaluable to us as we continue to expand our footprint with the most innovative caregiver support solutions in the market,” said Goldberg.

“I am really pleased to be joining Torchlight at this critical point in our country’s history when we are all realizing how critical caregivers are,” said Harsha. “Now, more than ever, scalable expert solutions are required to provide the most equity and inclusion in making caregiver support accessible to the millions of families in need, especially those struggling to remain productive and engaged in the workforce.”

About Torchlight

At Torchlight, we believe that caring is everyone’s business and caring is good business. We are the only complete caregiver support solution for employers and member organizations. We offer solutions informed by data and, thus, are built for better results. Our approach includes a user-friendly digital platform and a team of expert advisors. No matter the age, stage or concern, Torchlight’s decision-support tools, caregiving knowledge base, and human expertise combine to reduce stress and enhance outcomes for both families and their sponsoring organizations more cost-effectively than call center or concierge-only solutions. Because getting caregivers the right resources, in the right ways, right from the beginning should be business as usual. Learn more at http://www.torchlight.care, or email press@torchlight.care.

Share article on social media or email:

Read The Ingredients Launches New Big Bites


Our Big Bites maximize convenience with unparalleled flavor so that you can enjoy healthy and natural foods, anytime and anywhere.

Read The Ingredients, the creators of the Breakfast Loaf, has announced the release of the new Read The Ingredients Big Bites. Big Bites are available in two vegan and gluten-free flavors — Chocolate Chip and Double Chocolate.

The Big Bites have the consistency and taste of a less sweet Blondie (chocolate chip) or decadent Brownie (double chocolate) without the guilt. Each package of Big Bites has two servings per package to allow for delicious snacking/dessert or a full meal option. Big Bites are high in protein, and fiber, low in sugar, and are made with 100% plant-based whole food ingredients, with no preservatives or added alcohol sweeteners.

The new Big Bites are jam packed with nutrition and taste. Key Big Bite takeaways include:

  • SNACK OR MEAL: 1 Big Bite package is as filling as 2 of “other bars,” but much healthier
  • PLANT-BASED: All Big Bites are 100% plant-based
  • PROTEIN: Each package is packed with 14g pea protein
  • LOW SUGAR: No less than 65:1 calorie to sugar ratio
  • HIGH FIBER: 8g-10g of Dietary Fiber helps maintain gut health
  • MACRONUTRIENT RICH: Focusing on healthy fats and fiber in addition to protein
  • CONSISTENCY: Baked, not pressed, so the consistency will be like a moist brownie
  • ONLY NATURAL INGREDIENTS: If you can’t find it fresh in the grocery store, we avoid it!
  • All products are GLUTEN-FREE.

“We are proud to offer products that taste great, are super convenient, and immediately can become part of someone’s everyday routine,” said Bobbi Giudicelli, Cofounder of Read The Ingredients. “Our Big Bites maximize convenience with unparalleled flavor so that you can enjoy healthy and natural foods, anytime and anywhere.”

The mission of Read The Ingredients is simple, “Eating Clean, Finding your Energy, Living your Passion” is what is most important. Read The Ingredients strives to power each day and to provide the right fuel.

Read The Ingredients Big Bites are now available online at https://rtifoods.com/collections/big-bites along with The Read The Ingredients Loaves. Learn more at https://rtifoods.com/

Follow Read The Ingredients

https://www.instagram.com/readtheingredients/

https://www.facebook.com/RTIFoods

Media Contact

Christina Towle

BuzzBright PR

609.651.3529

Share article on social media or email:



Papa Expands Support for Aging Americans During the Pandemic with the Launch of Papa Health


News Image

With companionship at our core, we have a unique opportunity to encourage and facilitate medical care into the home.

Papa, a service that provides older adults and families with companionship and assistance with everyday tasks, today announced the launch of Papa Health. The comprehensive health management platform expands on the company’s existing services and is aimed at improving health outcomes of older adults and families.

Papa Health offers virtual primary care, urgent care, and chronic care management to its members through the Papa platform. The new service connects members with their Papa Doc virtually, while their Papa Pal is alongside the member and can help them navigate the appointment and provide transportation and care facilitation. Papa Pals are youthful, energetic, and caring companions who provide support and assistance to plan members.

Researchers believe that SDoH (Social Determinants of Health) drive more than 80 percent of health outcomes (1). Papa Pals also serve as “boots-on-the-ground,” making sure that beyond doctors’ appointments, members are eating the right foods, exercising, and are taking their medications.

“Engaging in a healthy lifestyle is imperative to leading a long, fulfilling life and our Papa Pals represent the missing link in delivering high-quality and effective healthcare to older adults,” said Joel Rabasco, Head of Papa Health. “Whether it’s helping coordinate a successful virtual primary care visit, or providing a trusted companion to assist in chronic care management, their guidance and advocacy will lead to dramatically better health outcomes for our members.”

Since launching in Miami, FL in 2018, Papa has seen dramatic growth, with plans to be in all 50 states by January 2021. Company growth has accelerated due to the COVID-19 pandemic and membership has increased 500 percent year-over-year.

“Never before has it been more important to support older adults and families throughout the aging journey,” said Andrew Parker, Founder and CEO of Papa. “With companionship at our core, we have a unique opportunity to encourage and facilitate medical care into the home, where our members prefer to be for routine consultations and healthcare planning.”

Papa services are available through health plan providers, including Aetna, AvMed, Florida Blue Medicare, Humana, Priority Health, and Regence Blue Shield, among many others.

For more information please visit: http://www.papa.health

About Papa

Papa is a family on-demand service providing companionship and care to older adults and families through an expansive client base of Medicare Advantage and state managed Medicaid health plans. Papa was founded in 2017 in Miami, FL. For more information, visit joinpapa.com.

Sources:

(1) https://healthpayerintelligence.com/news/addressing-the-real-implications-of-social-determinants-of-health

Share article on social media or email:

DocASAP Launches Comprehensive Solution for Coordinating COVID-19 Vaccinations Nationwide


News Image

DocASAP, the industry’s most advanced patient access and engagement platform for health systems, health plans and physician groups, today announced it is offering a COVID-19 Vaccination Coordination Solution to help healthcare providers and payers meet the urgent demand for vaccinating the nation.

The initiative will require handling the complexity of engaging healthy Americans and scheduling appointments for the two-dose vaccination over a multi-week window, while scaling to accommodate potentially 660 million vaccination appointments nationwide. Compared in scope, there were a total of 477 million primary care physician appointments in the U.S. in 2016, according to CDC’s latest report.

DocASAP’s COVID-19 Vaccination Coordination Solution will help providers and payers guide people through the vaccination process with pre-appointment engagement, online appointment scheduling and reminders, and post-appointment wellness tracking. This will help reduce the burden on staff and call centers to manage the sheer volume and complexity of these appointments, and better coordinate the influx so providers can effectively deliver the needed care. DocASAP will support the phased approach to rolling out vaccinations, beginning with front-line healthcare staff.

“The healthcare community has been resilient in responding to the pandemic as it has tested us at each step along the way,” said Dr. David B. Nash, founding dean emeritus of Jefferson College of Population Health. “2021 will be no different as it presents the next challenge: vaccinating our nation at scale. Coordinating this will mean guiding our communities through the entire vaccination process. DocASAP will help navigate millions of people to this crucial vaccination and redefine what we aspire to be the new normal, a healthy nation.”

DocASAP’s COVID-19 Vaccination Coordination Solution

DocASAP’s comprehensive digital solution is composed of the following capabilities:

  • Pre-appointment Engagement: Healthcare organizations can create outbound vaccination campaigns that target specific populations, helping increase awareness and promote scheduling appointments.
  • Online Appointment Scheduling and Reminders: Through healthcare organizations’ websites and apps, people can self-schedule both vaccination appointments in one go. Providers can set scheduling rules to help manage capacity and access across different care settings and locations offering the vaccine, including setting the date difference required between the first and second vaccination. Custom questions can be added to capture valuable health information. Automated digital confirmations and reminders can be sent for each scheduled appointment to help educate and prepare individuals for their visit and decrease no-shows. Those who don’t show up for their vaccination can be delivered a reminder to reschedule the vaccination.
  • Post-Vaccination Wellness Tracking: Vaccine recipients can be prompted to assess and track their wellness following their appointment. Those experiencing adverse reactions will be directed to seek appropriate medical attention.
  • Record Vaccine Data: Vaccine visits can be added to the patient’s electronic medical record (EMR) and support the need for mandatory state-based reporting.

According to a recent survey by DocASAP, once a COVID-19 vaccine becomes widely available, 84% of respondents plan to get it. When asked where you would feel safest receiving the COVID-19 vaccine, the top selection from respondents was the doctor’s office (48%), followed by hospital (33%), pharmacy (29%), urgent care (20%) and retail/grocery stores with a walk-in clinic (15%).

“As we come closer to having the COVID-19 vaccine available for distribution in the United States, DocASAP is committed to doing the right thing in supporting our nation, providers and communities,” said Puneet Maheshwari, co-founder and CEO of DocASAP. “We will be working closely with the healthcare community to help them coordinate access to these vaccinations. Together, we will navigate these challenging times and continue to help providers and payers connect patients and members to the right care, when they need it.”

About DocASAP

DocASAP provides the industry’s most advanced patient access and engagement platform for health systems, health plans and physician groups. DocASAP empowers organizations to navigate patients to the optimal provider and care setting at the right time throughout their access journey, helping improve outcomes, reduce costs and create a better patient experience. Backed and promoted in the market by Aetna, Optum and UnitedHealthcare, DocASAP builds unique payer-provider connections with an eye toward simplified access, increased care compliance and improved population risk management. For more information, visit http://docasap.com or follow on Twitter @DocASAP.

Share article on social media or email:



Target ALS Announces Second Round of 2020 Grant Recipients Focused on Discovering and Developing ALS Biomarkers


The Target ALS Diagnosis Initiative

We are now at a juncture where reliable biomarkers are an increasingly acute need. We look forward to the contribution of these consortia in this search, which could greatly improve the lives of ALS patients.

Target ALS announced today the grantees receiving funding for new projects focused on ALS biomarker discovery and development, resulting from a call for proposals issued in the spring. In accordance with the requirements of the Target ALS grantmaking process, collaboration between academic investigators and the pharma/biotech industry was required to apply. This funding builds on $5 million in grants awarded to projects earlier this year, in collaboration with The Association for Frontotemporal Degeneration (AFTD) targeting applicable treatments and biomarkers for both ALS and FTD.

“Listening to what our scientific community needs to advance their work, and responding with innovative approaches and resources is how we help exponentially advance ALS research,” said Target ALS CEO, Manish Raisinghani, MBBS, Ph.D. “We are now at a juncture where reliable biomarkers are an increasingly acute need. We look forward to the contribution of these consortia in this search, which could greatly improve the lives of ALS patients.”

Four projects were selected by the Target ALS Independent Review Committee based on their potential to advance ALS biomarker discovery and development. A brief overview of each newly funded project is provided below.

The members of the selected consortia receiving funding are:

  • Ruth Luthi-Carter (AC Immune), Ghazaleh Sadri-Vakili, Clotilde Lagier-Tourenne, Steven Arnold and James Berry (Massachusetts General Hospital)
  • Yi Chen (Biogen), Jiou Wang and Phil Wong (Johns Hopkins University)
  • Erez Eitan (NeuroDex Inc.), Sabrina Paganoni (Massachusetts General Hospital), Jeff Rothstein (Johns Hopkins University)
  • Toby Ferguson (Biogen), Tim Miller and Cindy Ly (Washington University), Randall Bateman (Washington University)

These grants will be awarded as one of three key pillars within The Target ALS Diagnosis Initiative, a $15 million comprehensive effort to discover ALS biomarkers that Target ALS announced last week. This research initiative is the first of its kind — developed in response to the input of over 100 scientists and other thought leaders, who universally identified ALS biomarkers as a critical unmet need to diagnose the disease early, track its progression and provide reliable measures for new treatments.

The grantees will also have open access to all of the tools and resources made available through the organization in order to inform and advance their work, including human biosamples, genomic datasets, and stem cells. For a full list of scientific resources, click here.

The Target ALS Diagnosis Initiative will also include a five-year natural history study, as well as a Biofluid and Genomics core that will exponentially improve the access to, and impact of, human biosamples on research. This new core is the eighth in a suite of resources offered by Target ALS to scientists worldwide with no strings attached.

Details of the 2020 ALS Biomarker Funding Awards:

1 – AC Immune’s high-sensitivity biofluid assays for detection of TDP-43 as an ALS biomarker

Ruth Luthi-Carter (AC Immune), Ghazaleh Sadri-Vakili, Clotilde Lagier-Tourenne, Steven Arnold and James Berry (Massachusetts General Hospital)

The accumulation of abnormal forms of the Transactive Response DNA-Binding Protein (TDP-43) is a prevalent feature of amyotrophic lateral sclerosis (ALS). Although pathological TDP-43 can be detected in brain tissue post-mortem, current bioassays are insufficient to quantify these species in patients, limiting their ability to accurately diagnose and track disease progression. Leveraging its proprietary SupraAntigenTM technology platform, AC Immune has generated a range of highly specific TDP-43-binding antibodies that are designed to reliably and non-invasively quantify neuropathological forms of TDP-43 in biofluids from people living with ALS. The grant will accelerate development of these novel antibody-based tests into robust assays suitable for use in ALS clinic and trials. Planned studies under this grant will evaluate the ability of AC Immune’s antibodies to identify ALS, correlate with disease evolution and predict clinical progression.

AC Immune’s expertise in molecular diagnostics and the biochemical and clinical expertise of the Healey Center for ALS at Massachusetts General Hospital will significantly facilitate the development and validation of these new assays. This collaboration will ensure progress toward establishing biomarkers helpful in diagnosis and staging of ALS.

2 – Identification of novel biomarkers for TDP-43-associated protein expression and signaling in longitudinal CSF samples

Yi Chen (Biogen), Jiou Wang and Phil Wong (Johns Hopkins University)

The altered protein homeostasis is a common pathogenic theme across major neurodegenerative disease. The discovery of TDP-43 cytoplasmic aggregates occurring in neurons and glia cells as the central pathological hallmark in ALS and FTD led to a flurry of investigations designed to clarify how TDP-43 aggregation drives neuronal loss. However, cells with cytoplasmic aggregates invariably exhibit nuclear clearance of TDP-43, suggesting the possibility that loss of TDP-43 function could underlie cell death in ALS-FTD. Subsequent studies suggest that the loss of TDP-43 functions and signaling are closely involved in disease processes.

The goal of this project is to identify biomarkers associated with TDP-43 functions and related signaling pathways. Since the TDP-43 proteinopathy is the most predominant pathological marker of ALS, identification of biomarkers on TDP-43 functions would allow better monitoring of the disease in patients to enable clinical trial testing. Our study is designed to search for novel biomarkers for TDP-43-associated protein expression and signaling in patients’ tissues and biofluids. The study will build on our research on the TDP-43 functions and signaling pathways and the industrial experience in biomarker identification.

3 – Neuron-derived exosomes as a biomarker platform for Amyotrophic lateral sclerosis

Erez Eitan (NeuroDex Inc.), Sabrina Paganoni (Massachusetts General Hospital), Jeff Rothstein (Johns Hopkins University)

Extracellular vesicles (EVs) are nanosized lipid vesicles released by cells in all tissues and contain proteins and RNA cargo that reflect their cell of origin. Isolation of Neuron-Derived Extracellular vesicles (NDEs) from the blood is an innovative liquid biopsy option in neurology, with a high potential to generate novel diagnostic, prognostic, monitoring and pharmacodynamic biomarkers in ALS.

The partners to this consortium have already demonstrated that the protein cargo in the NDEs of sporadic ALS patients is different from controls and could potently be utilized for accurate diagnosis. The goals of this consortium are to: Expand and finalize the biomarker signature measured within isolated NDEs; provide a better resolution to the correlation between the NDEs’ cargo, postmortem brain and induced pluripotent stem cells derived neurons from the same individuals; and test the biomarker signature in a larger patient population.

4 – Characterization of Neurofilament light chain isoforms and post-translational modifications in blood and CSF of ALS patients using mass spectrometry

Toby Ferguson (Biogen), Tim Miller and Cindy Ly (Washington University), Randall Bateman (Washington University)

Neurofilaments (NFs) are key cytoskeletal proteins that regulate axon integrity and have immense potential as a biomarker for neuronal injury and neurodegenerative disease. In particular, neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) have emerged as promising CSF and serum biomarkers for ALS based on the ability of ELISA-based methods to discriminate ALS from both healthy controls and disease mimics. Studies also suggest that NF concentrations may correlate with disease severity and survival.

However, existing immunoassay methods are unable to discriminate between alternative isoforms or post-translational modifications that may occur in the disease state. In contrast, high-resolution proteomic analyses can uncover disease-specific modifications such as truncations or chemical modifications that may better reflect disease characteristics. For instance, a proteomic approach used by Dr. Randall Bateman to examine tau in Alzheimer’s disease (AD) determined that phosphorylation at specific sites, such as ptau 217 or ptau 181, preferentially occurs in AD, correlates with pathology, and is an early, strong predictor of disease onset that outperforms total tau levels. This collaboration proposes to characterize the native isoforms of NF in CSF and blood of ALS and controls with mass spectrometry to identify novel disease-specific isoforms and evaluate their prognostic capability and performance as pharmacodynamic markers.

ABOUT TARGET ALS

Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. We envision a world in which no one dies of ALS and play a unique role in the battle against this disease. Founded in 2013 by former New York City deputy mayor Dan Doctoroff — who lost both his father and uncle to ALS — our approach is breaking down barriers and silos that previously inhibited research results. We do this through our Target ALS Innovation Ecosystem, which facilitates unparalleled collaboration between researchers from academia and the pharma/biotech industry. The Target ALS Innovation Ecosystem has revolutionized the field in just seven years through collaborations that have resulted in the first potential treatments since ALS was identified in 1869.

To date, the Target ALS Innovation Ecosystem, which launched in 2013 and set the groundwork for The Target ALS Diagnosis Initiative, has yielded 175+ research projects, 12+ therapeutic targets and five clinical trials, to date.

ABOUT THE TARGET ALS DIAGNOSIS INITIATIVE

Target ALS launched the first-ever comprehensive effort to discover ALS biomarkers — The Target ALS Diagnosis Initiative — through which the organization will invest $15 million in collaborative grantmaking and the development of new scientific resources. The initiative was developed in response to input from over 100 scientists, patients, caregivers and other thought leaders. They universally identified ALS biomarkers as a critical unmet need to diagnose the disease early, track its progression and provide reliable measures for new treatments.

The Target ALS Diagnosis Initiative strategically focuses on three promising areas:

  • Establishing new ALS biomarker-focused collaborative funding opportunities to fuel new projects for discovery and development of ALS biomarkers
  • Creating a five-year natural history study that will integrate longitudinal biofluid collection, clinical-grade speech, language and respiratory measures, clinical and demographic information, as well as genomic datasets from ALS and control cases
  • Developing an integrated Biofluid and Genomics core that will exponentially improve the impact of human biosamples on research through the integration of longitudinal biofluids, genomic datasets and postmortem tissue with expedited, no-strings-attached access to samples worldwide

U.S. Dermatology Partners is pleased to welcome Dermatology Nurse Practitioner, Kelsey Mason, to their Lees Summit location


Lees Summit, MO Dermatology Nurse Practitioner Kelsey Mason

Kelsey Mason, NP

U.S. Dermatology Partners is pleased to welcome Dermatology Nurse Practitioner Kelsey Mason to its Lees Summit, Missouri office.

Kelsey Mason earned her Master of Science in Nursing – Family Nurse Practitioner Degree in 2013 from Cox College in Springfield, Missouri where she graduated at the top of her class. Prior to that, she received her Bachelor of Science in Nursing Degree from Truman State University in Kirksville, Missouri in 2010 where she graduated magna cum laude.

After graduating, she practiced internal medicine/pediatrics as a foundation to her eventual goal of exclusively practicing dermatology. She has always had an interest in dermatology and treated a wide variety of skin conditions within the scope of her internal medicine/pediatrics practice. She was initially drawn to dermatology because of her personal experience as a former acne patient, and how its treatment helped to optimize her overall self-confidence as a teenager.

She later became Southern Illinois University Division of Dermatology’s first mid-level provider and served as an adjunct faculty member. Kelsey’s clinical interests include skin cancer detection and management, acne, rosacea, and psoriasis.

The most rewarding part of her job is providing patient education on the best practices for skincare and developing relationships with her patients in order to customize treatment plans to their specific dermatologic needs. Recognizing the psychosocial impact that dermatological conditions can have on a patient, she seeks every opportunity to improve skin conditions and thereby improve quality of life.

Kelsey is a member of the Sigma Theta Tau International Nursing Honor Society, the Dermatology Nurse Practitioner Society, and the Dermatology Nurses Association.

When not treating patients, Kelsey enjoys lap swimming, traveling, scuba diving, hiking, writing, playing the piano, St. Louis Cardinals baseball, and spending time with friends and family.

To schedule an appointment call 816-524-4747.

About Dermatology and Skin Cancer Centers

Dermatology and Skin Cancer Centers was founded in 1987 by Dr. Glenn Goldstein and was one of the first practices to offer Mohs Micrographic Surgery for high-risk skin cancer patients. Headquartered in the Kansas City area, Dermatology and Skin Cancer Centers, now a part of U.S. Dermatology Partners, is recognized as one of the top treatment centers in the nation for skin cancer prevention, diagnosis, and treatment. Our physician team remains dedicated to the treatment and prevention of skin cancers. Our state-of-the-art facilities are designed with the patient experience in mind and feature the latest technologies and procedures across all areas of dermatology, including general medical dermatology, surgical dermatology, plastic surgery, and cosmetic and aesthetic dermatology.

About U.S. Dermatology Partners

As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners’ patients not only have access to general medical, surgical, and cosmetic skin treatments through its coordinated care network, but also benefit from the practice’s strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery. To learn more, visit usdermatologypartners.com.

Share article on social media or email:

CK Office Furniture Study Finds Mental Health Improved For 61% People Who Worked From Home During Covid-19


61.54% of people said their mental health improved working from home.

Since the outset of the coronavirus pandemic earlier this year, people all over the world have speculated on how the dramatic shift in working habits would affect the mental health of employees having to work from home. Working from home has become more and more popular in recent decades, thanks largely due to technological advances meaning that remote working is a much more viable option than in recent years.

What we wanted to understand is how people have adapted to working from home as a result of COVID-19 and how it has affected their mental health.

We surveyed 186 employees across the US between the ages of 18 and 60 who worked from home during the pandemic and uncovered the following data highlights. For the full set of data head to our website CK Office Furniture.

How has working from home affected mental health?

61.54% of respondents said that they felt their mental health had improved working from home

38.46% felt that working from home had a negative effect on their mental health

What’s interesting is that even in the midst of uncertainty and economic turmoil, individuals felt that working at home actually made an improvement on their mental health.

How do remote workers rate their mental health?

We asked participants to rank their mental health between 1-10 (10 being the highest) when required to work in the office and when working from home during the pandemic.

For working from the office, the average response was 6. For working from home, the average response was 7, so this improved slightly while working from home.

Work life balance

Having a poor work life balance can have a negative impact on mental health, as we know this can lead to stress and other complications for workers who do not have boundaries between their work and home life.

We asked participants how they felt working from home during the COVID-19 crises has affected their work life balance and 50.27% of respondents felt their work life balance was better! Another 27.57% said it was about the same so less than a quarter of people felt it was worse.

We have also published the full data set along with an infographic that you can download on our website CK Office Furniture. If you want to use our results as part of a news article, blog or other content we just ask that you link back to our blog as the source!

Share article on social media or email:

Help.org Names the Best Drug and Alcohol Rehab Centers in Deerfield Beach


News Image

Help.org, a trusted online resource for individuals who struggle with addiction and their loved ones, has announced the Best Rehab Facilities in Deerfield Beach, FL for 2021. The informational guide recognizes the top 16 rehab facilities based on cost, treatment options, location, accompanying services and more.

According to recent studies, drug overdose is the leading cause of death among people under age 50. In Deerfield Beach, deaths related to opioid abuse increased significantly from 2011 to 2015. Substance abuse among adolescents is also escalating in Deerfield Beach with 55 percent of high school students reported using alcohol, 38 percent reported using marijuana, 8 percent reported using prescription drugs without a valid prescription, and 2 percent reported using heroin. With the growing need for accessible and high-quality rehab programs, Help.org has developed a unique ranking process to help connect individuals with treatment providers that meet their needs.

The Help.org research team analyzed thousands of facilities across the country and then identified the most cost-effective and highest rated programs in larger cities like Deerfield Beach. Each facility was evaluated based on rehabilitation services, treatment approaches, cost, special programs for unique demographics and ancillary services. The website also provides information about drug use and side effects as well as educational articles. For a detailed listing of the Best Rehab Facilities in Deerfield Beach, FL please visit https://www.help.org/drug-and-alcohol-rehab-centers-in-deerfield-beach-fl

2021 Best Rehab Facilities in Deerfield Beach, FL (in alphabetical order)

FHE Health

505 Federal Highway #2 Deerfield Beach, FL 33441

866-702-8041

1st Step Behavioral Health

3773 North Federal Highway Pompano Beach, FL 33064

866-971-5531

Gracious Care Recovery Solutions, Inc.

201 North Federal Highway Deerfield Beach, FL 33441

855-923-3733

Legacy Healing Center – Alcohol & Drug Rehab Pompano

803 NW 2nd Avenue Pompano Beach, FL 33060

954-800-4557

Banyan Treatment Center Pompano

950 North Federal Highway, Suite 115 Pompano Beach, FL 33062

830-240-1594

Ocean Breeze Recovery

2413 East Atlantic Boulevard Pompano Beach, FL 33062

855-679-3255

Immersion Recovery Center

3333 South Congress Avenue, Suite 401 Delray Beach, FL 33445

561-529-9008

Lifeskills South Florida

1431 SW 9th Avenue Deerfield Beach, FL 33441

954-212-9708

Addiction Solutions of Florida

6115 Lyons Road Coconut Creek, FL 33073

561-600-0308

Boca Recovery Center

971 South Dixie Highway West Pompano Beach, FL 33060

800-516-4357

Simple Path Recovery

1990 North Federal Highway, Suite A Pompano Beach, FL 33062

855-467-3625

Changes Treatment and Recovery

2310 East Atlantic Boulevard Pompano Beach, FL 33062

954-990-7171

The Retreat of Broward

100 NW 17th Avenue Pompano Beach, FL 33069

888-812-4111

Sunlight Recovery

505 South Federal Highway, Suite 2 Deerfield Beach, FL 33441

833-657-0999

Transformations Treatment Center

14000 South Military Trail Delray Beach, FL 33484

877-203-4690

Evolutions Treatment Center

2901 West Cypress Creek Road Fort Lauderdale, FL 33309

833-818-3031

ABOUT HELP.ORG

Help.org is an online resource for individuals who struggle with addiction and their loved ones. The website provides the latest research through scientifically proven methods, community recovery resources as well as information about local financial assistance. Help.org’s team of researchers, activists and writers work together with addiction counselors and other professionals to offer useful and accurate resources to help individuals seeking recovery. To learn more, visit https://www.help.org/.

Share article on social media or email: